Form 8-K - Current report:
SEC Accession No. 0001193125-25-178947
Filing Date
2025-08-12
Accepted
2025-08-12 16:07:27
Documents
13
Period of Report
2025-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d452012d8k.htm   iXBRL 8-K 28813
2 EX-99.1 d452012dex991.htm EX-99.1 85595
  Complete submission text file 0001193125-25-178947.txt   239883

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fate-20250807.xsd EX-101.SCH 2876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20250807_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20250807_pre.xml EX-101.PRE 10829
16 EXTRACTED XBRL INSTANCE DOCUMENT d452012d8k_htm.xml XML 3565
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 251206679
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)